VistaGen Therapeutics, Inc.
VTGN
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adulā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.24
Price0.00%
$0.00
1Y
Price
Market Cap
$9.889m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-3554.2%
EBITDA Margin-3499.8%
Net Profit Margin-3483.9%
Free Cash Flow Margin-3554.2%
EBITDA Margin-3499.8%
Net Profit Margin-3483.9%
Free Cash Flow MarginRevenue
$1.269m
+161.3%
1y CAGR+225.2%
3y CAGR+138.8%
5y CAGREarnings
-$69.685m
-35.5%
1y CAGR-20.1%
3y CAGR-21.1%
5y CAGREPS
-$1.83
-12.0%
1y CAGR+20.1%
3y CAGR+11.3%
5y CAGRBook Value
$35.520m
$48.564m
Assets$13.044m
Liabilities$1.044m
DebtDebt to Assets
2.2%
-
Debt to EBITDAFree Cash Flow
-$66.436m
-57.3%
1y CAGR-24.2%
3y CAGR-20.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company